Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 30, 2026 73 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTRUM-006 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... December 3, 2020 How NatWest Group are making a difference this Giving Tuesday November 29, 2022 Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in... April 10, 2024 Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant... January 19, 2022 Load more HOT NEWS Cómo puede ayudar la terapia del piso pélvico a las personas... Decorated Veteran Learns She Has Triple-Positive Breast Cancer While Pregnant with... 7 images that defined cancer policy in 2022 Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal...
